KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Exchange Rate Effect (2017 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Exchange Rate Effect for 9 consecutive years, with -$10.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Exchange Rate Effect rose 91.74% year-over-year to -$10.0 million, compared with a TTM value of $21.0 million through Dec 2025, up 112.07%, and an annual FY2025 reading of $21.0 million, up 112.07% over the prior year.
  • Exchange Rate Effect was -$10.0 million for Q4 2025 at Teva Pharmaceutical Industries, down from -$9.0 million in the prior quarter.
  • Across five years, Exchange Rate Effect topped out at $146.0 million in Q4 2022 and bottomed at -$123.0 million in Q2 2022.
  • Average Exchange Rate Effect over 5 years is -$21.7 million, with a median of -$32.0 million recorded in 2021.
  • Peak annual rise in Exchange Rate Effect hit 404.17% in 2022, while the deepest fall reached 2360.0% in 2022.
  • Year by year, Exchange Rate Effect stood at -$48.0 million in 2021, then skyrocketed by 404.17% to $146.0 million in 2022, then tumbled by 53.42% to $68.0 million in 2023, then tumbled by 277.94% to -$121.0 million in 2024, then skyrocketed by 91.74% to -$10.0 million in 2025.
  • Business Quant data shows Exchange Rate Effect for TEVA at -$10.0 million in Q4 2025, -$9.0 million in Q3 2025, and -$5.0 million in Q2 2025.